Epidemiology and reporting of randomized trials employing re-randomization of patient groups: A systematic survey

Contemporary Clinical Trials

Volumn 28, Issue 3, 2007, Pages 268-275

  Mills, Edward J ^a   Kelly, Steven ^c   Wu, Ping ^b   Guyatt, Gordon H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Methodology; Randomized trials; Re randomization; Systematic review

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DATA EXTRACTION; DRUG DOSE REGIMEN; DRUG INDUSTRY; EPIDEMIOLOGICAL DATA; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; METHODOLOGY; OPTIMAL DRUG DOSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SAMPLE SIZE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; HUMANS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY;

EID: 33847320108     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2006.09.002     Document Type: Article

References (25)

1. Chan A.W., and Altman D.G. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 365 9465 (2005) 1159-1162
2. McDermott M.P., Hall W.J., Oakes D., and Eberly S. Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 23 6 (2002) 635-649
3. DuBuske L.M., Grossman J., Dube L.M., Swanson L.J., and Lancaster J.F. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. Am J Manag Care 3 4 (1997) 633-640
4. Nemoto T., Horton J., Simon R., Dao T.L., Rosner D., Cunningham T., et al. Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer 49 10 (1982) 1988-1993
5. Meade M.O., Guyatt G.H., Cook R.J., Groll R., Kachura J.R., Wigg M., et al. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med 163 2 (2001) 490-493
6. Jaynes E.T. Confidence intervals vs. Bayesian intervals. In: Harper W.L., and Hooker C.A. (Eds). Foundations of Probability Theory, Statistical Inference, and Statistical Theories of Science (1976), D. Reidel, Dordrecht 175
7. Graham D.Y., and Evans D.G. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev Infect Dis 12 Suppl 1 (1990) S68-S72
8. Soares H.P., Daniels S., Kumar A., et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. Br Med J 328 (2004) 22-24
9. Devereaux P.J., Choi P.T., El-Dika S., Bhandari M., Montori V.M., Schunemann H.J., et al. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol 57 12 (2004) 1232-1236
10. Capra W.B. Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints. Control Clin Trials 25 2 (2004) 168-177
11. Leonardi C.L., Papp K.A., Gordon K.B., Menter A., Feldman S.R., Caro I., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 3 Pt 1 (2005) 425-433
12. Heyn R.M., Joo P., Karon M., Nesbit M., Shore N., Breslow N., et al. BCG in the treatment of acute lymphocytic leukemia. Blood 46 3 (1975) 431-442
13. Ryttig K.R., Flaten H., and Rossner S. Long-term effects of a very low calorie diet (Nutrilett) in obesity treatment. A prospective, randomized, comparison between VLCD and a hypocaloric diet + behavior modification and their combination. Int J Obes Relat Metab Disord 21 7 (1997) 574-579
14. Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., Halsted C.H., Heber D., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Jama 281 3 (1999) 235-242
15. Martenyi F., Brown E.B., Zhang H., Koke S.C., and Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 181 (2002) 315-320
16. http://www.nationalmssociety.org/Brochures-Comparing.asp (Accessed January 10, 2006).
17. Senn S. Crossover Trials in Clinical Research (1993), Wiley., Chichester. 0-471-93493-3
18. Hozo I., Djulbegovic B., Clark O., and Lyman G.H. Use of re-randomized data in meta-analysis. BMC Med Res Methodol 5 1 (2005) 17
19. Mills E.J., Wu P., Gagnier J., and Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 26 4 (2005) 480-487
20. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276 8 (1996) 637-639
21. Altman D.G., and Bland J.M. Statistics notes. Treatment allocation in controlled trials: why randomise?. BMJ 318 7192 (1999) 1209
22. Mills E., Loke Y.K., Wu P., Montori V.M., Perri D., Moher D., et al. Determining the reporting quality of RCTs in clinical pharmacology. Br J Clin Pharmacol 58 1 (2004) 61-65
23. Contopoulos-Ioannidis D.G., Ntzani E., and Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am J Med 114 6 (2003) 477-484
24. Bhandari M., Busse J.W., Jackowski D., Montori V.M., Schunemann H., Sprague S., et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Cmaj 170 4 (2004) 477-480
25. Lexchin J., Bero L., and Djulbegovic B. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J 326 (2003) 1167-1170